索拉非尼治疗肝细胞癌机制的研究进展  

Mechanisms of sorafenib in the treatment of hepatocellular carcinoma

作　　者：姚方一 林原[1] 唐泽耀[1] 

机构地区：[1]大连医科大学药理教研室,辽宁大连116044

出　　处：《现代肿瘤医学》2014年第9期2213-2216,共4页Journal of Modern Oncology

基　　金：国家自然科学基金资助项目(编号:30772601)

摘　　要：索拉非尼(多吉美,Sorafenib)是唯一被批准用于治疗晚期原发性肝细胞癌(hepatocellular carcinoma,HCC)的口服多激酶抑制剂。随着索拉非尼临床应用的发展,其抗癌机制被越来越多的人关注。索拉非尼不仅能作用于RAF/MEK/ERK通路、shp 1/STAT3相关通路、Wnt/β-catenin通路和内质网途径,还能影响相关基因和酶类,从而达到抑制肿瘤细胞增殖和肿瘤新生血管生成的作用。本文就近年来索拉非尼治疗HCC机制的研究进展作一综述。Sorafenib(Nexavar)is the only oral multi- kinase inhibitor which has been approved in the treatment of advanced hepatocellular carcinoma(HCC). With the development of its clinical applications,sorafenib's anti- cancer mechanisms have been more and more concerned. Sorafenib can not only act on the RAF /MEK /ERK pathway,shp 1 /STAT3 pathway,Wnt /β- catenin pathway and endoplasmic reticulum pathway,but also affect the genes and enzymes,then inhibits proliferation and angiogenesis. This review provides an overview of the underlying mechanisms of sorafenib in the treatment of HCC.

关 键 词：索拉非尼 肝细胞癌 细胞凋亡 未折叠蛋白反应 组蛋白甲基化转移酶 信号转导与转录激活因子3 

分 类 号：R735.7[医药卫生—肿瘤]